Background: Adiponectin and leptin are adipose tissue-derived hormones, shown to have opposing associations with the metabolic syndrome and coronary heart disease (CHD). This study evaluated the association between the leptin/adiponectin ratio and the components of the metabolic syndrome in a cohort with CHD. Methods and results: This cross-sectional study included data from 105 subjects (men ¼ 91), undergoing first-time elective coronary artery bypass grafting (CABG). Leptin and adiponectin concentrations were determined by enzyme-linked immunosorbent assay (ELISA). Association was found between the leptin/adiponectin ratio and homeostatic model assessment (HOMA) (r s ¼ 0.34, P ¼ 0.0006), fasting insulin concentrations (r s ¼ 0.37, P ¼ 0.0001), fasting glucose concentrations (r s ¼ 0.24, P ¼ 0.01), systolic blood pressure (r s ¼ 0.20, P ¼ 0.05), diastolic blood pressure (r s ¼ 0.24, P ¼ 0.02), waist circumference (r s ¼ 0.55, P , 0.0001), body mass index (BMI) (r s ¼ 0.55, P , 0.0001) and waist/hip ratio (r s ¼ 0.38, P ¼ 0.0001). A significant difference was found in ratios between those with and without insulin resistance (HOMA . 3 and HOMA 3) (P ¼ 0.029) and those with and without metabolic syndrome, defined by the International Diabetes Federation, (P , 0.001). However, using receiver operating characteristic (ROC) analysis and assessment of area under curve (AUC), the leptin/adiponectin ratio did not perform significantly better than its components. Conclusion: In patients with severe CHD, the leptin/adiponectin ratio was not found to be a robust tool to distinguish patients with and without insulin resistance and those with and without the metabolic syndrome.
Introduction
Leptin and adiponectin are adipose tissue-derived hormones involved in energy homeostasis. In 1994, Zhang et al. 1 identified the first of the adipose tissue-derived hormones, leptin, a product of the ob gene. Leptin is considered a satiety hormone. Lack of the functional gene in knockout mice leads to hyperphagia and severe obesity. 1 Congenital lack of the functional gene in humans results in severe childhood obesity, delayed maturation of the reproductive system and immune dysfunction. 2, 3 Adiponectin was first identified in 1995. 4 It is a protein coded for by a gene on chromosome 3q27. Evidence suggests adiponectin enhances the action of insulin, 5 stimulates insulin secretion in vitro and in vivo 6 and possibly has a central effect at the arcuate hypothalamus stimulating food intake and decreasing energy expenditure during fasting. 7 Both have been found to be cross-sectionally and prospectively associated with the metabolic syndrome 8, 9 and coronary heart disease (CHD), with leptin increasing and adiponectin decreasing. It has been proposed that leptin stimulates the development of atherosclerosis and adiponectin inhibits the process. However, this relationship is more controversial with some reports suggesting there has been overestimation of the association of the adipokines with CHD. 10, 11 Assuming that the proposed associations are true, we sought to determine whether combining these two variables as a ratio, leptin/adiponectin, resulted in an accurate predictor of the metabolic status of a patient in a cohort of patients with severe CHD. Strong correlations between the adipokines could improve understanding of the pathogenesis of the metabolic syndrome and atherosclerosis and offer a novel potential treatment pathway.
Method
A total of 105 unselected patients referred for first-time elective coronary artery bypass surgery (CABG) at King's College Hospital (London, UK) between January 2003 and December 2003 participated in the study. The study population was 87% men (n ¼ 91), 90.5% Caucasian (n ¼ 95), 8.5% South Asian (n ¼ 9) and 0.95% Arab (n ¼ 1) with a mean age of 66.3 (range 42 -81) years. Patients were excluded if they had symptomatic heart failure or an acute coronary syndrome in the previous six months. Patients were recruited from a preadmission clinic one month prior to surgery when smoking status (current or within the last six months) was ascertained and anthropometric measurements taken. The characteristics of the patients are described in Table 1 . All patients were taking HMG-CoA reductase inhibitors and antiplatelet agents, 42% were taking angiotensin-converting enzyme inhibitors, 76% b-adrenoceptor blockers, 44% calcium channel antagonists and 22% a diuretic. Drugs were omitted for 24 h prior to surgery. On the morning of surgery, blood was obtained for measurement of lipids, fasting blood glucose, insulin, leptin and adiponectin concentrations. The study protocol and collection of samples were approved by the local research ethics committee and all subjects provided written informed consent.
Metabolic syndrome
Ninety-nine patients were assessed for metabolic syndrome using the International Diabetes Federation (IDF) criteria. Of those, 66% (n ¼ 65) were assessed as having the syndrome.
Plasma assays
Assays for serum total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and glucose were carried out in the hospital biochemistry laboratory (Advia 2400, Siemens Healthcare, Camberley, UK). Leptin and adiponectin were measured using a commercially available enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, MN, USA). The intra-assay coefficient of variation (CV) for leptin was 5.9 -6.9% (3.15 -24.6 mg/L) and for adiponectin 2.5 -4.7% (1980 -14,300 mg/L). The inter-assay CV for leptin was 11.6 -8.7% (2.7 -26.1 mg/L) and for adiponectin 5.8 -6.9% (2050 -15,700 mg/L). Homeostatic model assessment (HOMA) greater than 3.0 was used as a marker of insulin resistance; the validity of this cut-off has been previously determined. 12 
Statistical analysis
Continuous variables are presented as mean + standard error of the mean (SEM). The data were tested for a normal distribution using the Shapiro -Wilk test. Spearman's rank correlation was used to examine the relationship between variables. The Mann -Whitney U test was used to assess associations between non-parametric data-sets. The adiponectin and leptin concentrations were log transformed and stepwise multiple regression analysis performed to identify independent predictors of adiponectin and leptin concentrations. A value of P , 0.05 was considered statistically significant. Analysis was performed using Analyse-it General 1.65 and SPSS version 14.0.
Results

Leptin and adiponectin
To compare the strength of associations of the leptin/ adiponectin ratio, the differences were first determined using the components of the ratio.
In this cohort, significantly lower concentrations of adiponectin were detected in patients with metabolic syndrome (mean adiponectin concentration 5061 + 527 mg/L) compared with those without (mean adiponectin concentration 7111 + 911 mg/L) where P ¼ 0.04. However, no significant difference was observed in adiponectin concentrations between those with or without insulin resistance as defined as a HOMA . 3, P ¼ 0.33. Similar findings were seen when assessing the associations of leptin alone. Significantly higher concentrations of leptin were found in patients with metabolic syndrome (mean + SD leptin concentration 19.35 + 2.04 mg/L) compared with those without (mean leptin concentration 11.15 + 1.44) where P ¼ 0.004. However, no significant difference was observed in leptin concentrations between those with or without insulin resistance as defined as a HOMA . 3, P ¼ 0.0724.
Leptin/adiponectin ratio and its correlates
We went on to examine the associations between the components of the metabolic syndrome and the leptin/adiponectin ratio in this large unselected group (Table 2) .
Association was found between the leptin/adiponectin ratio and a number of the components. Positive correlations were identified with: HOMA, used as a surrogate measure of insulin resistance (r s ¼ 0.34, P ¼ 0.0006); fasting insulin concentrations (r s ¼ 0.37, P ¼ 0.0001) and fasting glucose concentrations (r s ¼ 0.24, P ¼ 0.01); systolic blood pressure (r s ¼ 0.20, P ¼ 0.05) and diastolic blood pressure (r s ¼ 0.24, P ¼ 0.02); waist circumference (r s ¼ 0.56, P , 0.0001) and waist/hip ratio (r s ¼ 0.5, P ¼ 0.0001) and body mass index (BMI) (r s ¼ 0.53, P , 0.0001). A negative correlation was identified when examining the association between the Variation in HDL (r s ¼ 20.15, P ¼ 0.15), triglycerides (r s ¼ 0.17, P ¼ 0.09) and cholesterol (r s ¼ 20.19, P ¼ 0.07) were not found to be associated with the leptin/adiponectin ratio.
Leptin/adiponectin ratio and the metabolic syndrome
As described earlier, metabolic syndrome has been found to be cross-sectionally and prospectively associated with changes in circulating leptin and adiponectin concentrations. 8, 9 This study aimed at determining whether alterations in the leptin/adiponectin ratio could be used to distinguish patients with insulin resistance from those without. Insulin resistance was defined as a HOMA index .3, which equates to the upper quartile of HOMA results in this study. Significantly higher ratios of leptin/adiponectin were found in those with a HOMA ,3 compared with those with a HOMA .3 (P ¼ 0.029).
We also assessed the ability of the ratio to distinguish patients with the metabolic syndrome from those without the syndrome. We detected significantly lower ratios of leptin/adiponectin in those who had metabolic syndrome, as defined by the IDF, and those who did not (P , 0.001).
Stepwise multiple regression analysis of logarithmically transformed leptin/adiponectin ratios was performed to identify components that were independently associated with the leptin/adiponectin ratio. Waist circumference (r ¼ 0.51, P , 0.001) and fasting glucose concentrations (r ¼ 0.56, P ¼ 0.01) were found to be independent predictors of the ratio.
Receiver operating characteristic curves
The test performance was assessed using receiver operating characteristic (ROC) curves. The sensitivity and specificity of the leptin/adiponectin ratio at determining the presence of metabolic syndrome or HOMA .3 were assessed and compared with the individual components of the ratio (Table 3) .
When the leptin/adiponectin ratio was identifying patients with metabolic syndrome, with a sensitivity of 80%, the specificity was 59% compared with specificities of 38% with leptin and 35% with adiponectin alone. The area under curve (AUC) for the leptin/adiponectin ratio and metabolic syndrome was found to be 0.73 (0.63 -0.84), only marginally better than leptin, 0.68 (0.57 -0.74), or adiponectin, 0.63 (0.51 -0.75), alone. There was no significant difference between these ROCs.
When the leptin/adiponectin ratio was identifying patients with a HOMA . 3, with a sensitivity of 75%, the specificity was 38% compared with specificities of 36% with leptin and 32% with adiponectin alone. The AUC for the leptin/adiponectin ratio and insulin resistance was found to be 0.62 (0.62 -0.75), only marginally better than leptin, 0.60 (0.46 -0.74), or adiponectin, 0.56 (0.43 -0.69), alone. There was no significant difference between these ROCs.
Discussion
This report identifies the leptin/adiponectin ratio to be a more useful marker of metabolic syndrome and insulin resistance (using HOMA as a surrogate) than each of its individual components alone. However, the advantage was small, particularly when assessing the data on insulin resistance.
Leptin/adiponectin ratio as a metabolic marker
Studies of the association of the leptin/adiponectin ratio are limited. The leptin/adiponectin ratio has been previously proposed as an indicator of atherosclerosis, insulin resistance and the metabolic syndrome. 13 -17 In 2004, Satoh et al 13 were the first group to demonstrate the greater sensitivity of the leptin/adiponectin ratio than its components in predicting atherosclerosis in obese type 2 diabetic patients and proposed its use as a potential atherogenic index in this population. Support was lent to this finding when the leptin/adiponectin ratio was found to have close correlation with carotid intima-media thickness, a surrogate marker of atherosclerosis, again in a population with type 2 diabetes. 14 This finding was promptly replicated in healthy subjects. 15 The same group also demonstrated the leptin/adiponectin ratio to have stronger correlations with several anthropometric, metabolic and clinical parameters than the individual adipokines. Correlations in this healthy population were detected between the leptin/adiponectin ratio and BMI, waist, hip, waist-to-hip ratio, systolic blood pressure, intima-media thickness, HDL, apolipoprotein A-I, glucose and HOMA. 15 Our study supports these findings, showing the ratio to be associated with many of the components of the metabolic syndrome. However, we did not find any association between the leptin/adiponectin ratio and the patients' lipid profiles, apart from LDL. Recently, the leptin/adiponectin ratio was shown to be better able to classify subjects with or without metabolic syndrome and have a stronger association with the components of the syndrome than adiponectin or leptin alone in older Chinese adults, using the IDF definition of the syndrome, 16 a finding supported by our study, but in a predominantly Caucasian population. Most recently, the leptin/ adiponectin ratio has been identified as a useful measure of insulin sensitivity in non-diabetic individuals; it was demonstrated to be at least as strongly associated with the gold standard measure of insulin resistance (clamp M/I value) as other frequently used methods such as fasting insulin or HOMA. 17 Our study suggests that the leptin/ adiponectin ratio may be a less useful predictor of insulin resistance than suggested by Finucaine et al. 17 in our mixed population of treated diabetic and non-diabetic patients with a significant co-morbidity. Unlike previous studies, notably the MONICA/KORA study, we did not find either adipokine to be significantly independently associated with insulin resistance. 18 The subjects in our study were patients with severe CHD; we supposed that all would have deranged ratios 13 -15 and further derangements caused by the metabolic syndrome would enable us to distinguish between the groups. However, it has recently been demonstrated that this logic may be flawed. In 2010, the MONICA/KORA study of 333 case subjects with incident CHD and 1728 non-case subjects concluded that the ratio did not improve prediction of CHD compared with either adipokine alone. 19 They examined carotid intima thickening as a surrogate marker of atherosclerosis and found that after controlling for metabolic syndrome, carotid intima thickness is associated with plasma adiponectin levels but not with the leptin/adiponectin ratio. 20
Limitations
(1) This study is cross sectional and therefore does not indicate a cause and effect relationship between the leptin/ adiponectin ratio and insulin resistance or the metabolic syndrome. (2) The study examined an older, predominantly male, predominantly Caucasian population. Although this is representative of the population within the UK with CHD, it may make the findings of this study less applicable to other groups. (3) HOMA was used as a surrogate marker of insulin sensitivity as only blood samples were available for analysis. 21 The gold standard remains the hyperinsulinaemic euglycaemic clamp. 22 
